Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.

Driouich, Jean-Sélim; Bernadin, Ornéllie; Touret, Franck; de Lamballerie, Xavier; Nougairède, Antoine

Driouich, Jean-Sélim; Bernadin, Ornéllie; Touret, Franck; de Lamballerie, Xavier; Nougairède, Antoine.

Afiliação

Driouich JS; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM, 1207, Marseille, France.
Bernadin O; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM, 1207, Marseille, France.
Touret F; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM, 1207, Marseille, France.
de Lamballerie X; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM, 1207, Marseille, France.
Nougairède A; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM, 1207, Marseille, France. Electronic address: antoine.nougairede@univ-amu.fr.

Antiviral Res ; 215: 105638, 2023 07.

Article em En | MEDLINE | ID: mdl-37207822

Assuntos

COVID-19; Animais; Cricetinae; Humanos; SARS-CoV-2; Anticorpos Monoclonais Humanizados; Anticorpos Neutralizantes; Anticorpos Antivirais

Palavras-chave

Hamster model; Monoclonal antibody; Omicron variants; SARS-CoV-2; Sotrovimab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Animals / Humans Idioma: En Revista: Antiviral Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google